TY - JOUR
T1 - The Landmark Series
T2 - Randomized Control Trials Examining Perioperative Chemotherapy and Postoperative Adjuvant Chemotherapy for Resectable Colorectal Liver Metastasis
AU - Kawaguchi, Yoshikuni
AU - Vauthey, Jean Nicolas
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Surgical resection remains the only curative treatment option for patients with colorectal liver metastases (CLM). However, the high recurrence rate after resection has led physicians to investigate multidisciplinary treatments combining surgery and medical therapy. Currently, the evidence to support medical therapy in patients with resectable CLM is limited. For patients with resectable CLM, the National Comprehensive Cancer Network Guidelines (version 2.2020) for colon and rectal cancer recommends either upfront surgery and postoperative adjuvant chemotherapy or preoperative chemotherapy followed by surgery and postoperative adjuvant chemotherapy. This article reviews randomized control trials regarding medical therapy before and after curative resection of CLM, and summarizes the updated long-term report of the New EPOC trial which investigated the addition of cetuximab to perioperative chemotherapy for patients with resectable CLM.
AB - Surgical resection remains the only curative treatment option for patients with colorectal liver metastases (CLM). However, the high recurrence rate after resection has led physicians to investigate multidisciplinary treatments combining surgery and medical therapy. Currently, the evidence to support medical therapy in patients with resectable CLM is limited. For patients with resectable CLM, the National Comprehensive Cancer Network Guidelines (version 2.2020) for colon and rectal cancer recommends either upfront surgery and postoperative adjuvant chemotherapy or preoperative chemotherapy followed by surgery and postoperative adjuvant chemotherapy. This article reviews randomized control trials regarding medical therapy before and after curative resection of CLM, and summarizes the updated long-term report of the New EPOC trial which investigated the addition of cetuximab to perioperative chemotherapy for patients with resectable CLM.
UR - http://www.scopus.com/inward/record.url?scp=85087672841&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087672841&partnerID=8YFLogxK
U2 - 10.1245/s10434-020-08777-z
DO - 10.1245/s10434-020-08777-z
M3 - Review article
C2 - 32803551
AN - SCOPUS:85087672841
SN - 1068-9265
VL - 27
SP - 4263
EP - 4270
JO - Annals of surgical oncology
JF - Annals of surgical oncology
IS - 11
ER -